Sign In
Buy JNJ
$244.88
+3.88 (+1.61%)
At Close: Jun 25, 2026
Dow Stock Eyes Key Trendline After Guidance Update
09:15am, Tuesday, 05'th Dec 2023
Johnson & Johnson (NYSE:JNJ) is in focus this morning, after the pharma giant offered up its guidance for 2024 and beyond.
J&J's (JNJ) Bladder Cancer Drug Gets FDA's Breakthrough Tag
09:01am, Tuesday, 05'th Dec 2023
FDA grants Breakthrough Therapy Designation to J&J's (JNJ) TAR-200 for high-risk non-muscle-invasive bladder cancer based on data from the phase IIb SunRISe-1 study.
Johnson & Johnson Ticks Higher Following Guidance Release
08:07am, Tuesday, 05'th Dec 2023
The pharmaceutical and medical-device company offered long-term targets at an investor meeting.
Johnson & Johnson forecasts as much as 6% sales growth in 2024
07:18am, Tuesday, 05'th Dec 2023
Johnson & Johnson on Tuesday forecast revenue growth of 5-6% for the next year, as it banks on strong demand for cancer treatments Darzalex and Carvykti and resilient sales of blockbuster drug Stelara
Johnson & Johnson Vs. Pfizer: Better Pharma Stock?
12:55am, Tuesday, 05'th Dec 2023
Johnson & Johnson demonstrates better R&D efficiency and has a larger patent portfolio compared to Pfizer. JNJ's product pipeline in the Pharmaceutical segment has more late-stage developments, suppor
Buffett Just Sold Dividend Kings Johnson & Johnson And Procter & Gamble - Buy This One Instead
01:00pm, Monday, 04'th Dec 2023
Warren Buffett - known for making successful investments in Dividend Kings over the years - recently sold two popular Dividend Kings. We look at why he may have made these sales. We also share a diffe
The 7 Best Ways to Invest $1,000 in the Stock Market Now
09:21am, Monday, 04'th Dec 2023
The economy is showing strong signs of improvement as we get into the holiday mood. Investment choices are many, but investors with a limited amount need to conduct thorough research.
Google Bard picks 5 stocks to buy in 2024
08:11am, Monday, 04'th Dec 2023
After Alphabet introduced the Google Bard platform (NASDAQ: GOOGL), which ignited enthusiasm for artificial intelligence (AI), the technology has rapidly showcased its capabilities across diverse indu
December Dogs Of The Dow: 3 Buyable, 5 Watchable
07:51am, Monday, 04'th Dec 2023
"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.”
Warren Buffett Just Closed His Position in This Dividend Giant. Should You?
05:30am, Sunday, 03'rd Dec 2023
Buffett's Berkshire Hathaway sold all of its Johnson & Johnson shares in the recent quarter. This marks the billionaire investor's exit from the pharmaceutical industry.
How To Build A High-Potential Dividend Portfolio Combining Dividend Income With Dividend Growth
02:00pm, Saturday, 02'nd Dec 2023
In this article, I will demonstrate how you could build a diversified dividend portfolio that blends dividend income with dividend growth, aiming towards achieving an attractive Total Return. I will u
Johnson & Johnson Stock Gains a Bull Ahead of Analyst Day
12:19pm, Friday, 01'st Dec 2023
Shares are lower this year, thanks to an ongoing legal situation, but UBS says those worries are factored into the stock.
Cramer's Stop Trading: Johnson & Johnson
10:43am, Friday, 01'st Dec 2023
CNBC's Jim Cramer explains why he is keeping an eye on shares of Johnson & Johnson.
Johnson & Johnson: Sleep Well At Night With The Only AAA-Rated Dividend Aristocrat
03:11pm, Thursday, 30'th Nov 2023
As a Dividend King with six decades of dividend growth to its credit and a AAA credit rating from S&P, Johnson & Johnson stands in a league of its own. The healthcare behemoth reported solid sales and
Income Kings: 7 Blue-Chip Dividend Stocks for Reliable Returns
11:06am, Thursday, 30'th Nov 2023
In a volatile stock market, navigating investment avenues that promise reliable returns remains a key priority for investors. The article delves into the world of income-centric investments.
